Full Year 2024 Results Key Financial Results Revenue: US$62.0m (down 60% from FY ...

Sutro Biopharma is undergoing a seismic shake-up —jettisoning its CEO, half of its workforce, its lead candidate and its manufacturing facility in a major bid to save cash.

Sutro Biopharma (STRO) announced expanded data in a late-breaking oral presentation from the dose-optimization portion of the REFRalphaME-O1 ...

Sutro Biopharma Inc (STRO) extends its cash runway and strengthens partnerships while navigating workforce cuts and ...

Sutro Biopharma, a Bay Area oncology biotech company, is laying off around half its staff, switching up its leadership team ...

Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate ...

Sutro Biopharma, Inc.’s STRO share price has dipped by 35.19%, which has investors questioning if this is right time to buy.

Sutro Biopharma (NASDAQ:STRO – Get Free Report) was downgraded by research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research note issued on Friday, MarketBeat.com ...

Jane Chung, president and chief operating officer at Sutro, is replacing Bill Newell as chief executive as the company starts ...

Sutro Biopharma (Nasdaq: STRO), a US biotechnology company, has announced significant organizational changes, including a ...

The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or ...

President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell ...